未知生产厂商
Cy 503 is under investigation in clinical trial NCT00658437 (Aviscumine for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy).
Cy 503 is under investigation in clinical trial NCT00658437 (Aviscumine for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
